InspireMD Files Q2 2024 10-Q
Ticker: NSPR · Form: 10-Q · Filed: Aug 5, 2024 · CIK: 1433607
| Field | Detail |
|---|---|
| Company | Inspiremd, INC. (NSPR) |
| Form Type | 10-Q |
| Filed Date | Aug 5, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001, $1 thousand |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, medical-devices
Related Tickers: NSPR
TL;DR
InspireMD's Q2 10-Q is in. Check financials and ops.
AI Summary
InspireMD, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Key financial data and operational highlights for the second quarter of 2024 are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of InspireMD, Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a medical device company, InspireMD faces inherent risks related to product development, regulatory approvals, market adoption, and competition.
Key Numbers
- Q2 2024 — Reporting Period (Financial and operational data for the second quarter of 2024.)
- 2024-06-30 — Period End Date (The specific date through which financial information is reported.)
- 2024-08-05 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- InspireMD, Inc. (company) — Filer of the 10-Q report
- 20240630 (date) — End of the reporting period
- 20240805 (date) — Filing date of the report
- Saguaro Resources, Inc. (company) — Former company name
- NSPR (company) — Ticker symbol for InspireMD, Inc.
FAQ
What were InspireMD's key financial results for the quarter ending June 30, 2024?
The 10-Q filing for the period ending June 30, 2024, details InspireMD's financial results, though specific dollar amounts for revenue, net income/loss, and cash flow are not provided in the header information.
What is the primary business of InspireMD, Inc.?
InspireMD, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as indicated by its SIC code 3841.
When was InspireMD, Inc. formerly known as?
InspireMD, Inc. was formerly known as Saguaro Resources, Inc., with a date of name change on April 28, 2008.
What is the ticker symbol for InspireMD, Inc.?
The ticker symbol for InspireMD, Inc. is NSPR.
What is the fiscal year end for InspireMD, Inc.?
InspireMD, Inc.'s fiscal year ends on December 31.
Filing Stats: 4,655 words · 19 min read · ~16 pages · Grade level 14.2 · Accepted 2024-08-05 16:30:53
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NSPR Nasdaq Capital Mark
- $1 thousand — ,643 * Represents an amount less than $1 thousand The accompanying notes are an integra
Filing Documents
- form10-q.htm (10-Q) — 781KB
- ex31-1.htm (EX-31.1) — 19KB
- ex31-2.htm (EX-31.2) — 19KB
- ex32-1.htm (EX-32.1) — 7KB
- ex32-2.htm (EX-32.2) — 7KB
- 0001493152-24-030265.txt ( ) — 4062KB
- nspr-20240630.xsd (EX-101.SCH) — 30KB
- nspr-20240630_cal.xml (EX-101.CAL) — 47KB
- nspr-20240630_def.xml (EX-101.DEF) — 107KB
- nspr-20240630_lab.xml (EX-101.LAB) — 289KB
- nspr-20240630_pre.xml (EX-101.PRE) — 221KB
- form10-q_htm.xml (XML) — 555KB
Financial Statements
Financial Statements F-1 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 3 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 9 Item 4.
Controls and Procedures
Controls and Procedures 9 PART II Item 1.
Legal Proceedings
Legal Proceedings 10 Item 1A.
Risk Factors
Risk Factors 10 Item 5. Other Information 11 Item 6. Exhibits 12 2 Item 1. Financial Statements INSPIREMD, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE QUARTER ENDED JUNE 30, 2024 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Condensed Consolidated Balance Sheets F-2 - F-3 Condensed Consolidated Statements of Operations F-4 Condensed Consolidated Statements of Changes in Equity F-5 - F-8 Condensed Consolidated Statements of Cash Flows F-9 Notes to the Condensed Consolidated Financial Statements F-10 - F-16 F-1 INSPIREMD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (U.S. dollars in thousands) June 30, December 31, 2024 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 28,385 $ 9,640 Marketable securities 18,778 29,383 Accounts receivable: Trade, net 1,307 1,804 Other 450 648 Prepaid expenses 717 578 Inventory 2,206 2,106 TOTAL CURRENT ASSETS 51,843 44,159 NON-CURRENT ASSETS: Property, plant and equipment, net 1,595 1,060 Operating lease right of use assets 1,257 1,473 Funds in respect of employee rights upon retirement 964 951 TOTAL NON-CURRENT ASSETS 3,816 3,484 TOTAL ASSETS $ 55,659 $ 47,643 F-2 INSPIREMD, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (U.S. dollars in thousands other than share and per share data) June 30, December 31, 2024 2023 LIABILITIES AND EQUITY CURRENT LIABILITIES: Accounts payable and accruals: Trade 927 939 Other 6,038 5,081 TOTAL CURRENT LIABILITIES 6,965 6,020 LONG-TERM LIABILITIES- Operating lease liabilities 786 1,038 Liability for employees' rights upon retirement 1,145 1,084 TOTAL LONG-TERM LIABILITIES 1,931 2,122 COMMITMENTS AND CONTINGENT LIABILITIES - - TOTAL LIABILITIES 8,896 8,142 EQUITY: Common stock, par value $ 0.0001 per share; 150,000,000 shares authorized at June 30, 2024 and December 3
financial statements related disclosures
financial statements related disclosures. 2) In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its condensed consolidated financial statements disclosures. NOTE 4 – FAIR VALUE MEASUREMENTS Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. F-11 The Company's financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: SCHEDULE OF FINANCIAL ASSETS